Compare United States Copper Index Fund (CPER) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Charles River Laboratories Intl. Inc — how do they compare? United States Copper Index Fund trades at $40.11, while Charles River Laboratories Intl. Inc trades at $286.7 (market cap $13.46B). Which is the better fit depends on your goals.
| CPER | CRL | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.85 | $282.00 |
52-Week Low | $27.57 | $145.57 |
Market Cap | — | $13.46B |
Enterprise Value | — | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER (United States Copper Index Fund) trades at $40.345, up 0.41% with a bullish technical signal supported by moving averages. The copper market faces supply constraints from Chilean weather disruptions while AI and electrification demand drives prices to record highs. Recent news highlights copper's structural bull case with Citi targeting $15,000/tonne by year-end.
Copper's fundamental outlook remains strong due to AI infrastructure demand and supply constraints, though substitution risks and geopolitical tensions present headwinds. The ETF offers pure copper exposure amid favorable analyst sentiment, with technical indicators suggesting continued upward momentum near key resistance levels.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
